Neogenomics (NEO) Operating Income (2016 - 2025)
Historic Operating Income for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$13.4 million.
- Neogenomics' Operating Income rose 2710.18% to -$13.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$115.9 million, marking a year-over-year decrease of 2581.27%. This contributed to the annual value of -$115.9 million for FY2025, which is 2581.27% down from last year.
- Latest data reveals that Neogenomics reported Operating Income of -$13.4 million as of Q4 2025, which was up 2710.18% from -$27.0 million recorded in Q3 2025.
- Neogenomics' Operating Income's 5-year high stood at -$13.4 million during Q4 2025, with a 5-year trough of -$52.0 million in Q1 2022.
- Its 5-year average for Operating Income is -$29.6 million, with a median of -$27.4 million in 2025.
- Per our database at Business Quant, Neogenomics' Operating Income plummeted by 95056.76% in 2021 and then skyrocketed by 3876.23% in 2023.
- Quarter analysis of 5 years shows Neogenomics' Operating Income stood at -$41.6 million in 2021, then soared by 36.53% to -$26.4 million in 2022, then rose by 29.6% to -$18.6 million in 2023, then rose by 0.93% to -$18.4 million in 2024, then grew by 27.1% to -$13.4 million in 2025.
- Its Operating Income was -$13.4 million in Q4 2025, compared to -$27.0 million in Q3 2025 and -$47.6 million in Q2 2025.